Clinical Trial Update: A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates the efficacy and safety of JNJ-77242113 versus placebo and ustekinumab in moderate to severe plaque psoriasis; status is active not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• JNJ-77242113
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING